AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33978907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-Xa ≥ 0.1 IU/mL)
Trial: 33978907
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (anti-Xa < 0.1 IU/mL)
Trial: 33095760
Drug: Preventive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive chemotherapy (PC) with albendazole, coverage ranging from 49% to 85%.
Trial: 32529493
Drug: Rehabilitative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitative treatment (12 sessions, 2/week)
Trial: 35354682
Drug: Intra-articular steroid-lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid-lidocaine injection (IASLI)
Trial: 33326878
Drug: Trauma‐Informed Guilt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma‐Informed Guilt Reduction (TrIGR) therapy
Trial: 33326878
Drug: TrIGR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrIGR therapy
Trial: 34230526
Drug: Pinaverium 50
RxNorm normalized name: pinaverium 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium 50 mg, three times daily for 4 weeks
Trial: 33260253
Drug: Metronidazole (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (125 mg/mL) at 20 mg/kg PO q12h
Trial: 33260253
Drug: Metronidazole benzoate
RxNorm normalized name: Metronidazole Benzoate
DrugBank: Metronidazole benzoate (DB15759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole benzoate (25 mg/mL) at 20 mg/kg PO q12h
Trial: 33260253
Drug: Metronidazole benzoate
RxNorm normalized name: Metronidazole Benzoate
DrugBank: Metronidazole benzoate (DB15759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole benzoate (25 mg/mL) at 10 mg/kg PO q12h
Trial: 34420532
Drug: IMPaCT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPaCT therapy
Trial: 32461105
Drug: Tucatinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib (300 mg twice daily) in cohort A
Trial: 32461105
Drug: Tucatinib (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucatinib (750 mg once daily) in cohort B
Trial: 34506972
Drug: Bumetanide treatment
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide treatment for 91 days
Trial: 33686771
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (Er:YAG and Nd:YAG lasers)
Trial: 35383908
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) plus ipilimumab (IPI) (3 mg/kg + 1 mg/kg every 3 weeks for 4 cycles)
Trial: 35383908
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (SUN) (50 mg daily for four 6-week cycles)
Trial: 33934704
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA (1 g/day, 694 mg DHA and 397 mg EPA)
Trial: 32498226
Drug: Nonconsumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonconsumption of whole grains daily association with T2DM
Trial: 35940465
Drug: Oral Itrifal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Itrifal Hakim Ali (IHA) (10g/day) and topical Habb‐e‐Kalaf (HK)
Trial: 35940465
Drug: Oral Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Itraconazole (100 mg/day) and local Terbinafine (1%)
Trial: 36427054
Drug: Sequential dual-task
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dual-task measures of listening effort with varying signal-to-noise ratios (SNR)
Trial: 35020250
Drug: Restylane (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane (Group A) - Superficial injection (Group A1)
Trial: 35020250
Drug: Restylane (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane (Group A) - Deep injection (Group A2)
Trial: 35020250
Drug: Yishumei (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishumei (Group B) - Superficial injection (Group B1)
Trial: 35020250
Drug: Yishumei (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishumei (Group B) - Deep injection (Group B2)
Trial: 36198322
Drug: Deep learning-based
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning-based VMAT forward dose calculations using a convolutional neural network trained on dose of individual multi-leaf-collimator VMAT segments.
Trial: 36198322
Drug: Deep learning-based
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning-based VMAT forward dose calculations on previously unseen IMRT patients.
Trial: 33518152
Drug: Dietary arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary arsenic supplementation (0.95, 20.78, 40.67, and 60.25 mg/kg)
Trial: 36484428
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg for 13 weeks
Trial: 34726329
Drug: HM15136 (10-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM15136 (10-120 μg/kg)
Trial: 34726329
Drug: HM15136 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM15136 (80 μg/kg)
Trial: 34726329
Drug: HM15136 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM15136 (50 μg/kg or higher)
Trial: 32301204
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (1,000 mg/day)
Trial: 32012409
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin only (Group-A)
Trial: 32012409
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil with tamsulosin (Group-B)
Trial: 34709770
Drug: Type-1 collagen
RxNorm normalized name: WHITE SPIRIT TYPE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type-1 collagen cone (CC)
Trial: 33186772
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) 10 mg per day for 12 weeks
Trial: 32317292
Drug: NY‐ESO‐1/ISCOMATRIX vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NY‐ESO‐1/ISCOMATRIX vaccine
Trial: 34981548
Drug: Low-intensity, long-wavelength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity, long-wavelength red light therapy (LLRT) (power 0.4 mW, wavelength 635 nm) twice per day for 3 min each session
Trial: 32654603
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=14)
Trial: 33377160
Drug: Lowest tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest tertile of baseline serum bicarbonate (23.1 ± 1.6 mmol/L)
Trial: 33377160
Drug: Each mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each mmol/L decrease in serum bicarbonate
Trial: 32073417
Drug: Intracoronary prourokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary prourokinase administration
Trial: 32993574
Drug: Platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy and cetuximab
Trial: 34358514
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 3%, 5%, 10%, and 15% Piper guineense oil
Trial: 34358514
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 10% and 15% Piper guineense oil
Trial: 33400390
Drug: UC-MSC treatment
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC treatment
Trial: 33829271
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg thiamine daily
Trial: 33829271
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg thiamine daily
Trial: 33829271
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg thiamine daily
Trial: 33829271
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg thiamine)
Trial: 33849658
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (waiting period)
Trial: 32408253
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids (Arginine and Leucine) administered for 10 weeks at a dosage of 0.1 g/kg body mass/day
Trial: 38985488
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin daily
Trial: 38985488
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg aspirin daily
Trial: 32333512
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser combined with intradermal injection of PRP
Trial: 32333512
Drug: Intraderma injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraderma injection of noncross-linked hyaluronic acid
Trial: 36165508
Drug: Cilostazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (50 mg daily, increased to 100 mg/day after 2 weeks)
Trial: 33899498
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 5 mg and metoclopramide 10 mg
Trial: 33899498
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo (control group)
Trial: 32705528
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy for 1 month
Trial: 36103251
Drug: Universidade do
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universidade do Bebê (UBB) intervention consisting of monthly workshops focused on reading aloud and a book-lending library
Trial: 36028920
Drug: Standardized KS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized KS clinical evaluation tool, palliative care integration, standardized treatment, improved consultative services
Trial: 34602640
Drug: Hydromorphone 0.1
RxNorm normalized name: HYDROmorphone 0.1 mg/mL-NaCl 0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.1 mg/kg BW intramuscularly (IM)
Trial: 34602640
Drug: Hydromorphone 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 0.01 mg/kg BW pharmacopuncture at GV20 (GV)
Trial: 33184972
Drug: Hypoglossal Neurostimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglossal Neurostimulation therapy (HGNS)
Trial: 34078635
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (EBM) knowledge
Trial: 35939102
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 2% lidocaine at the port sites before incision
Trial: 34999348
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of recombinant human basic fibroblast growth factor (bFGF) + conventional medication
Trial: 33427546
Drug: E6011 400-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 400-mg
Trial: 32565444
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight)
Trial: 33476301
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies to SARS-CoV-2
Trial: 32844540
Drug: High dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysate magnesium (1.0 mmol/L)
Trial: 32844540
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate magnesium (0.5 mmol/L)
Trial: 33319628
Drug: γ‐T‐rich vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: γ‐T‐rich vitamin E mixture (two capsules daily for 7 or 14 days)
Trial: 34418014
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 15mg/Kg administered 15-30 minutes pre-surgery
Trial: 34418014
Drug: Fentanyl 2mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2mcg/kg administered at induction of anaesthesia
Trial: 35264846
Drug: Inhaled velsecorat
RxNorm normalized name: Velsecorat
DrugBank: Velsecorat (DB16347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled velsecorat (1872 µg)
Trial: 35264846
Drug: Inhaled velsecorat
RxNorm normalized name: Velsecorat
DrugBank: Velsecorat (DB16347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled velsecorat
Trial: 32762677
Drug: Integrated EMDR-Dialectical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated EMDR-Dialectical Behavioural Therapy (DBT)
Trial: 35841488
Drug: Machined neck
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined neck implants
Trial: 35841488
Drug: Rough neck
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rough neck implants
Trial: 32329771
Drug: Elevated progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Elevated progesterone concentrations among women in the lowest quintile of estradiol (<6.30 pg/mL)
Trial: 32329771
Drug: Elevated progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Elevated progesterone concentrations among women in higher quintiles of estradiol (Q2‐Q5; ≥6.30 pg/mL)
Trial: 33966678
Drug: Lurasidone (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40, 80, 120, or 160 mg)
Trial: 33966678
Drug: Lurasidone (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (combined doses)
Trial: 32853709
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical betamethasone valerate cream applied once a day after radiation
Trial: 33024992
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg twice per day for at least 6 months)
Trial: 33202066
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 or 2 g)
Trial: 35400633
Drug: Edoxaban treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban treatment
Trial: 35257962
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal 2 mg aflibercept (arm 1)
Trial: 35257962
Drug: Quarterly intravitreal
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quarterly intravitreal 2 mg aflibercept (arm 2)
Trial: 36324139
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 0.025% + conventional therapy (CTx)
Trial: 36324139
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 0.05% + conventional therapy (CTx)
Trial: 36324139
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue 0.1% + conventional therapy (CTx)
Trial: 36324139
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CTx) alone
Trial: 33801019
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation, 745 mg daily for an average of 12.4 years
Trial: 32112556
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care intervention (quarterly AF check-ups by trained nurses, monitoring of anticoagulation therapy, consultations from cardiologists)
Trial: 35136417
Drug: Manual reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual reduction (treatment group)
Trial: 33964855
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg vitamin D3/d
Trial: 32638614
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) plus routine physical therapy
Trial: 32638614
Drug: Sham HILT
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham HILT plus routine physical therapy
Trial: 34347950
Drug: REGEN-COV (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGEN-COV (1200 mg subcutaneous injection)
Trial: 32568065
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (starting at 500 mg three times daily, increasing to 1 g three times daily if serum bicarbonate < 22 mmol/l at 3 months)
Trial: 32997871
Drug: Cognitive Analytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Analytic Therapy (CAT) plus Treatment as Usual (TAU)
Trial: 33522061
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment condition involving toy-based interactions with caregivers.
Trial: 35523485
Drug: Epicardial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicardial injection of hiPSC‐CMs (1×10^8, 2×10^8, and 4×10^8 cells) during CABG surgery
Trial: 32471373
Drug: PMES plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMES plus antidepressant
Trial: 32471373
Drug: Sham plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham plus antidepressant
Trial: 35382961
Drug: Hydromorphone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone combined with ropivacaine (5 μg/kg hydromorphone + 0.2% ropivacaine)
Trial: 32339235
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (RT) with concurrent and adjuvant temozolomide (TMZ)
Trial: 32339235
Drug: Single modality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single modality treatment with temozolomide (TMZ)
Trial: 35920662
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g) and Taniborbactam (0.5 g) administered as a single intravenous infusion over 2 hours.
Trial: 32423930
Drug: XZK 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XZK 1200 mg once per day (OD group)
Trial: 32423930
Drug: XZK 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XZK 600 mg two times per day (TD group)
Trial: 34215704
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 200-400 mg/day
Trial: 34702123
Drug: Dapagliflozin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin plus standard treatment
Trial: 34279564
Drug: Daily coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily coffee intake
Trial: 33035457
Drug: Tazemetostat 800
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat 800 mg orally twice per day in continuous 28-day cycles
Trial: 32853747
Drug: Long-term albumin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term albumin administration
Trial: 32853747
Drug: On-treatment serum
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment serum albumin levels
Trial: 32853747
Drug: Patients whose
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients whose on-treatment serum albumin remained below normal
Trial: 33462580
Drug: Ivermectin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (400 µg/kg for 3 days)
Trial: 36037586
Drug: BUP/NX flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP/NX flexible model of care with flexible take-home dosing (n = 138)
Trial: 34001462
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation therapy (SCRT) followed by chemotherapy (FOLFOX ×8 or CAPOX ×5 cycles)
Trial: 34001462
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation therapy (SCRT) followed by chemotherapy
Trial: 32736184
Drug: Antidepressant trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant trials
Trial: 34037955
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise for 30 min per session, 5 times a week for 6 weeks with conventional treatment